Avalo Therapeutics, Inc. AVTX
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 87.51% | 15.53% | |||
| Gross Profit | -87.51% | -16.31% | |||
| SG&A Expenses | 18.16% | 4.90% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 50.79% | 5.56% | |||
| Operating Income | -50.79% | -5.87% | |||
| Income Before Tax | -85.24% | -44.36% | |||
| Income Tax Expenses | 50.00% | -90.77% | |||
| Earnings from Continuing Operations | -85.22% | -43.08% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -85.22% | -43.08% | |||
| EBIT | -50.79% | -5.87% | |||
| EBITDA | -50.83% | -5.87% | |||
| EPS Basic | 14.59% | -29.74% | |||
| Normalized Basic EPS | 14.58% | -30.89% | |||
| EPS Diluted | 14.59% | -29.35% | |||
| Normalized Diluted EPS | 14.58% | -30.89% | |||
| Average Basic Shares Outstanding | 116.85% | 10.28% | |||
| Average Diluted Shares Outstanding | 116.85% | 10.28% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||